130 related articles for article (PubMed ID: 24532305)
1. Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.
Pérez-Fidalgo JA; Bermejo B; Chirivella I; Martínez MT; González I; Cejalvo JM; Catoira I; Martínez P; Contel E; Lluch A
Clin Transl Oncol; 2014 Sep; 16(9):814-22. PubMed ID: 24532305
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial.
Abdel-Rahman O
Clin Transl Oncol; 2019 Feb; 21(2):239-245. PubMed ID: 29956074
[TBL] [Abstract][Full Text] [Related]
3. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
Chirivella I; Bermejo B; Insa A; Pérez-Fidalgo A; Magro A; Rosello S; García-Garre E; Martín P; Bosch A; Lluch A
Breast Cancer Res Treat; 2009 Apr; 114(3):479-84. PubMed ID: 18463977
[TBL] [Abstract][Full Text] [Related]
4. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
Cespedes Feliciano EM; Chen WY; Lee V; Albers KB; Prado CM; Alexeeff S; Xiao J; Shachar SS; Caan BJ
JAMA Oncol; 2020 Feb; 6(2):264-270. PubMed ID: 31804676
[TBL] [Abstract][Full Text] [Related]
5. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
[TBL] [Abstract][Full Text] [Related]
6. Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer.
Ladwa R; Kalas T; Pathmanathan S; Woodward N; Wyld D; Sanmugarajah J
Clin Breast Cancer; 2018 Oct; 18(5):e1181-e1187. PubMed ID: 29778788
[TBL] [Abstract][Full Text] [Related]
7. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
[TBL] [Abstract][Full Text] [Related]
8. A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.
Leonard RC; Mansi JL; Keerie C; Yellowlees A; Crawford S; Benstead K; Matthew R; Adamson D; Chan S; Grieve R;
Ann Oncol; 2015 Dec; 26(12):2437-41. PubMed ID: 26416895
[TBL] [Abstract][Full Text] [Related]
9. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
[TBL] [Abstract][Full Text] [Related]
10. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
11. Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.
Schraa SJ; Frerichs KA; Agterof MJ; Hunting JCB; Los M; de Jong PC
Eur J Cancer; 2017 Jul; 79():152-157. PubMed ID: 28494406
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
13. Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.
Lambertini M; Bruzzi P; Poggio F; Pastorino S; Gardin G; Clavarezza M; Bighin C; Pronzato P; Del Mastro L
Support Care Cancer; 2016 Mar; 24(3):1285-94. PubMed ID: 26306520
[TBL] [Abstract][Full Text] [Related]
14. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
Puhalla S; Mrozek E; Young D; Ottman S; McVey A; Kendra K; Merriman NJ; Knapp M; Patel T; Thompson ME; Maher JF; Moore TD; Shapiro CL
J Clin Oncol; 2008 Apr; 26(10):1691-7. PubMed ID: 18316792
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study.
Yamada A; Nakazawa K; Akazawa K; Narui K; Endo I; Hasegawa Y; Kohno N; Ishikawa T;
Anticancer Res; 2021 Feb; 41(2):1063-1068. PubMed ID: 33517316
[TBL] [Abstract][Full Text] [Related]
17. Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.
Matthews CM; Nymberg K; Berger M; Vargo CA; Dempsey J; Li J; Ramaswamy B; Reinbolt R; Sardesai S; Wesolowski R; Williams N; Lustberg M
J Oncol Pharm Pract; 2020 Apr; 26(3):572-579. PubMed ID: 31256745
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
19. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
20. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer.
Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P
Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]